Imprime PGG in Combination with Monoclonal Antibody Therapy Achieves 64 …PharmaLive (press release) (subscription)(BUSINESS WIRE)–Dec 10, 2012 – All subjects in a phase 1 study of high risk, chronic lymphocytic leukemia responded to the combination …
Imprime PGG in Combination with Monoclonal Antibody Therapy Achieves 64 …MarketWatch (press release)Research shows that early monoclonal antibody (mAb) therapy with alemtuzumab and rituximab is effective and could possibly delay first standard treatm…
TG Therapeutics, Inc. Announces Poster Presentation Highlights for Ublituximab …GlobeNewswire (press release)In vitro / in vivo results demonstrate superior efficacy with ublituximab compared to rituximab in primary central nervous system lymphomas, …
TG Therapeutics, Inc. Announces Poster Presentation Highlights for Ublituximab …MarketWatch (press release)In vitro / in vivo results demonstrate superior efficacy with ublituximab compared to rituximab in primary central nervous system lymphomas, in…
Rituximab Benefits Some APS Non-Criteria ManifestationsMonthly Prescribing Reference(HealthDay News) – Some patients with antiphospholipid syndrome with non-criteria manifestations may improve after treatment with rituximab, according to a study publ…
TODAY ON PHARMALIVE.COMPharmaLive (press release) (subscription)With a demonstrated ability to induce significantly greater ADCC activity over rituximab, TG-1101 is uniquely positioned to take advantage of the NK-cell activating properties exhibited by…
HealioIbrutinib Effective and Safe Treatment Option in CLLMedscapeAlthough chemoimmunotherapy approaches such as fludarabine, cyclophosphamide, and rituximab have markedly improved outcomes, primarily of younger, fit patients, fludarabine-based therapy…
Roche reports positive studies of MabThera given by subcutaneous injectionPipelineReview.com (press release)BASEL, Switzerland I December 8, 2012 I Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from two studies which showed that a fixed do…
 Healio |
Combination of ibrutinib and rituximab produced high response rates in high …
Healio ATLANTA — The combination of ibrutinib and rituximab produced favorable overall response rates among high-risk patients with chronic lymphocytic leukemia, according to study results presented at the 2012 American Society of Hematology Meeting and … |
AbbVie's Life After AbbottDailyFinanceOne of the drugs the company pins future hopes on is daclizumab, which is used to treat relapsing multiple sclerosis. A phase 3 clinical trial is currently under way for the drug in collaboration with Biogen . …